Want to see JP:4480 full AI Analyst Report?
Top Page
Medley
(4480)
Select Model
Select Model
Rating:59Neutral
Price Target:
¥2,936.00
▲(25.47% Upside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by mixed financial performance: strong revenue growth and positive cash flow are outweighed by sharp 2025 margin compression and increased leverage. Technicals are supportive due to a strong uptrend, but overbought readings raise near-term risk. Valuation is a headwind given the high P/E and no dividend yield data.
Positive Factors
Strong Revenue Growth
The substantial multi-year expansion indicates sustained market adoption and business scaling. Continued top-line growth provides a foundation for operating leverage and supports investment in the company’s healthcare information services platform.
Negative Factors
Sharp Margin Compression
The steep decline in bottom-line profitability weakens the quality of recent growth and reduces the company’s ability to convert revenue into reinvestment capital. Sustained margin pressure could limit earnings resilience despite healthy gross margin.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The substantial multi-year expansion indicates sustained market adoption and business scaling. Continued top-line growth provides a foundation for operating leverage and supports investment in the company’s healthcare information services platform.
Read all positive factors
Medley (4480) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥88.52B
Dividend YieldN/A
Average Volume (3M)504.45K
Price to Earnings (P/E)44.7
Beta (1Y)0.47
Revenue Growth24.03%
EPS Growth34.50%
CountryJP
Employees1,511
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)60.12
Shares Outstanding32,738,600
10 Day Avg. Volume497,800
30 Day Avg. Volume504,450
Financial Highlights & Ratios
PEG Ratio-1.19
Price to Book (P/B)5.08
Price to Sales (P/S)2.04
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)71.26
Revenue Forecast (FY)¥46.35B
Medley Business Overview & Revenue Model
Company Description
Medley, Inc., a company based in Japan, develops and manages digital platforms for both the recruitment and medical industries. Its operations are structured into three primary segments: HR Platform Business, Medical Platform Business, and New Ser...
How the Company Makes Money
null...
Medley Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
52
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.00B | 36.79B | 29.30B | 20.53B | 14.19B | 10.86B |
| Gross Profit | 25.51B | 23.19B | 18.92B | 13.59B | 9.72B | 6.99B |
| EBITDA | 5.68B | 5.01B | 4.00B | 4.50B | 2.14B | 1.25B |
| Net Income | 1.82B | 975.00M | 2.80B | 2.57B | 1.02B | 563.00M |
Balance Sheet | ||||||
| Total Assets | 45.38B | 41.25B | 45.41B | 25.52B | 22.04B | 20.33B |
| Cash, Cash Equivalents and Short-Term Investments | 12.04B | 8.57B | 19.00B | 15.35B | 14.42B | 14.29B |
| Total Debt | 18.83B | 16.09B | 15.18B | 1.66B | 2.38B | 3.11B |
| Total Liabilities | 30.42B | 26.45B | 25.19B | 7.89B | 6.87B | 6.28B |
| Stockholders Equity | 14.96B | 14.80B | 20.21B | 17.55B | 15.08B | 13.97B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.28B | 2.38B | 3.47B | 1.64B | 796.39M |
| Operating Cash Flow | 0.00 | 3.49B | 2.45B | 3.87B | 2.01B | 1.04B |
| Investing Cash Flow | 0.00 | -7.13B | -10.72B | -1.66B | -751.00M | -3.29B |
| Financing Cash Flow | 0.00 | -6.78B | 11.90B | -1.22B | -927.00M | 2.22B |
Medley Technical Analysis
Positive
2340.00
Price Trends
2186.78
Positive
2183.90
Positive
2210.51
Positive
Market Momentum
199.75
Negative
64.84
Neutral
56.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4480, the sentiment is Positive. The current price of 2340 is below the 20-day moving average (MA) of 2417.75, above the 50-day MA of 2186.78, and above the 200-day MA of 2210.51, indicating a bullish trend. The MACD of 199.75 indicates Negative momentum. The RSI at 64.84 is Neutral, neither overbought nor oversold. The STOCH value of 56.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4480.
Medley Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥1.19T | 25.90 | 12.38% | 1.16% | 15.76% | 13.53% | |
71 Outperform | ¥225.79B | 32.38 | ― | 0.43% | 18.89% | 11.66% | |
61 Neutral | ¥11.26B | 18.13 | ― | 5.30% | 36.94% | -31.50% | |
59 Neutral | ¥88.52B | 44.69 | 6.35% | ― | 24.03% | 34.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ¥2.15B | -4.11 | ― | ― | 14.84% | 30.67% |
* Healthcare Sector Average
JP:4480
Medley
2,687.00
203.00
8.17%
JP:2413
M3
1,778.50
-392.57
-18.08%
JP:4438
Welby Inc.
257.00
-81.00
-23.96%
JP:4483
JMDC Inc.
3,430.00
-727.77
-17.50%
JP:9341
GENOVA Inc.
633.00
8.74
1.40%
Medley Corporate Events
Medley Books One‑Off Extraordinary Loss from Subsidiary Merger, No Hit to Consolidated Profit
Aug 13, 2026
Medley, Inc. has reported an extraordinary loss of 218 million yen in its non‑consolidated results for the six months to June 30, 2026, stemming from a loss on extinguishment of tie‑in shares following the April 1 absorption‑type...
Medley to Cancel Treasury Shares and Sets 5% Holding Policy
Aug 13, 2026
Medley’s board has approved the cancellation of 930,000 common treasury shares, representing 2.84% of its issued stock before the move, with the effective date set for August 31, 2026. Following the cancellation, total issued shares will dec...
Medley to Pay First-Ever Dividend, Sets 30% Payout Target Amid Record Earnings
Aug 13, 2026
Medley, Inc., a Tokyo Stock Exchange Prime Market-listed digital and healthcare-focused company, has historically prioritized reinvesting earnings over paying dividends, leveraging internal capital to drive sustainable growth. Buoyed by record 202...
Medley Posts Profit Surge in First Half and Signals Shareholder Returns With Planned Dividend
Aug 13, 2026
Medley reported strong results for the six months to June 30, 2026, with net sales rising 22.8% year on year to ¥22.68 billion and EBITDA jumping 43.4%, driving a 131.2% surge in profit attributable to owners of the parent. Earnings per share...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.